# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001213900-22-074269
Filing Date
2022-11-21
Accepted
2022-11-21 17:01:10
Documents
7
Period of Report
2022-12-08

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | PROCY STATEMENT | def14a1122_actiniumpharma.htm | DEF 14A | 1594917
2 | GRAPHIC | tactinium_logo.jpg | GRAPHIC | 134661
3 | GRAPHIC | tflowchart_001.jpg | GRAPHIC | 414177
4 | GRAPHIC | tlinechart_001.jpg | GRAPHIC | 227980
5 | GRAPHIC | tproxy_001.jpg | GRAPHIC | 1026977
6 | GRAPHIC | tproxy_002.jpg | GRAPHIC | 1352507
7 | GRAPHIC | tsandesh_sig.jpg | GRAPHIC | 15747
| Complete submission text file | 0001213900-22-074269.txt |  | 5966093

Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36374 | Film No.: 221406557
SIC: 2834 Pharmaceutical Preparations